logo
ResearchBunny Logo
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

Medicine and Health

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

J. An, X. Li, et al.

This phase II study explored the combination of serplulimab and nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer, achieving an impressive 57.1% objective response rate and demonstrating durable clinical activity with manageable safety. Conducted by esteemed authors including Jusheng An and Xiumin Li, this research opens new avenues for cervical cancer treatment.

00:00
00:00
Playback language: English
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny